Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: A Randomized, Double-masked, Controlled Study
Latest Information Update: 08 Oct 2021
Price :
$35 *
At a glance
- Drugs Ranibizumab (Primary) ; Ranibizumab
- Indications Vitreous haemorrhage
- Focus Therapeutic Use
- 25 Jul 2018 Status changed from active, no longer recruiting to completed.
- 15 Oct 2014 Accrual to date is 104% according to United Kingdom Clinical Research Network record
- 15 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.